文献速递呼吸道感染呼吸危重症与机械通气

前列环素用于合并严重内皮病的COVID-19机械通气患者:多中心随机临床试验

Prostacyclin in Intubated Patients with COVID-19 and Severe Endotheliopathy: A Multicenter, Randomized Clinical Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2022-01-01

本研究为多中心随机临床试验,纳入需机械通气的COVID-19成人患者且血浆血栓调节蛋白>4 ng/ml,随机接受72小时前列环素1 ng/kg/min或安慰剂输注。主要结局28天内无机械通气存活天数中位数16.0天 vs 5.0天(差异10.96天,95%CI -5至21,P=0.07),28天死亡率21.9% vs 43.6%(RR 0.50,95%CI 0.24-0.96,P=0.06),7天内严重不良事件2.4% vs 12.8%(RR 0.19,95%CI 0.001-1.11,P=0.10)。结论:前列环素未显著减少28天内无机械通气存活天数,但所有分析点估计均倾向前列环素组,需更大样本研究。

要点

  • 前列环素未显著改善28天内无机械通气存活天数(P=0.07)。
  • 28天死亡率点估计倾向前列环素组(21.9% vs 43.6%),但差异未达显著。
  • 严重不良事件发生率两组均较低,前列环素组数值更低。

核心结论

  • 前列环素未显著减少28天内无机械通气存活天数,但所有分析点估计均倾向前列环素组,包括28天死亡率,需更大样本试验进一步验证。

研究设计与样本

  • 多中心随机临床试验,纳入需机械通气的COVID-19成人患者且血浆血栓调节蛋白>4 ng/ml,随机接受72小时前列环素1 ng/kg/min或安慰剂输注。

主要发现

  • 28天内无机械通气存活天数中位数:前列环素组16.0天(SD 12) vs 安慰剂组5.0天(SD 10),中位数差异10.96天(95%CI -5至21,P=0.07)。
  • 28天死亡率:前列环素组21.9% vs 安慰剂组43.6%(RR 0.50,95%CI 0.24-0.96,P=0.06)。
  • 7天内严重不良事件发生率:前列环素组2.4% vs 安慰剂组12.8%(RR 0.19,95%CI 0.001-1.11,P=0.10)。

关键数值与推荐

  • 主要结局为28天内无机械通气存活天数,未达统计学显著差异(P=0.07)。
  • 28天死亡率风险比0.50(95%CI 0.24-0.96,P=0.06),严重不良事件风险比0.19(95%CI 0.001-1.11,P=0.10)。

临床怎么用

  • 对于合并严重内皮病的COVID-19机械通气患者,前列环素输注未显著改善主要结局,但点估计提示可能获益,需权衡后个体化考虑并等待更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: The mortality in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who require mechanical ventilation remains high, and endotheliopathy has been implicated. Objectives: To determine the effect of prostacyclin infusion in mechanically ventilated patients infected with SARS-CoV-2 with severe endotheliopathy. Methods: We conducted a multicenter, randomized clinical trial in adults infected with coronavirus disease (COVID-19) who required mechanical ventilation and had a plasma level of thrombomodulin >4 ng/ml; patients were randomized to 72-hour infusion of prostacyclin 1 ng/kg/min or placebo. Measurements and Main Results: The main outcome was the number of days alive and without mechanical ventilation within 28 days. Key secondary outcomes were 28-day mortality and serious adverse events within 7 days. Eighty patients were randomized (41 prostacyclin and 39 placebo). The median number of days alive without mechanical ventilation at 28 days was 16.0 days (SD, 12) versus 5.0 days (SD, 10) (difference of the medians, 10.96 days; 95% confidence interval [CI], -5 to 21; P = 0.07) in the prostacyclin and the placebo groups, respectively. The 28-day mortality was 21.9% versus 43.6% in the prostacyclin and the placebo groups, respectively (risk ratio, 0.50; 95% CI, 0.24 to 0.96; P = 0.06). The incidence of serious adverse events within 7 days was 2.4% versus 12.8% (risk ratio, 0.19; 95% CI, 0.001 to 1.11; P = 0.10) in the prostacyclin and the placebo groups, respectively. Conclusions: Prostacyclin was not associated with a significant reduction in the number of days alive and without mechanical ventilation within 28 days. The point estimates, however, favored the prostacyclin group in all analyses, including 28-day mortality, warranting further investigation in larger trials. Clinical trial registered with www.clinicaltrials.gov (NCT04420741); EudraCT Identifier: 2020-001296-33.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Johansson PI, Søe-Jensen P, Bestle MH, et al. Prostacyclin in Intubated Patients with COVID-19 and Severe Endotheliopathy: A Multicenter, Randomized Clinical Trial. Am J Respir Crit Care Med. 2022. PMID: 34813414. doi:10.1164/rccm.202108-1855OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。